Evaluation of Etest method for determining fluconazole and voriconazole MICs for 279 clinical isolates of Candida species infrequently isolated from blood

Journal of Clinical Microbiology

Volumn 41, Issue 3, 2003, Pages 1087-1090

  Maxwell, M J ^a   Messer, S A ^a   Hollis, R J ^a   Boyken, L ^a   Tendolkar, S ^a   Diekema, D J ^a   Pfaller, M A ^a   Steele Moore, L ^b   Denys, G ^c   Staley, C ^d   Dipersio, J R ^e   Saubolle, M ^f   Wilson, M L ^g   Overturf, G D ^h   Peterson, L R ⁱ   Schreckenberger, P C ^j   Doern, G V ^k  

^a UNIVERSITY OF IOWA   (United States)

^b CHRISTIANA CARE HEALTH SYSTEM   (United States)

^c METHODIST HOSPITAL   (United States)

^d HENRY FORD HOSPITAL   (United States)

^e SUMMA HEALTH SYSTEM   (United States)

^f BANNER GOOD SAMARITAN MEDICAL CENTER   (United States)

^g DENVER HEALTH MEDICAL CENTER   (United States)

^h UNIVERSITY OF NEW MEXICO HOSPITAL   (United States)

ⁱ NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^j UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^k UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; VORICONAZOLE;

ARTICLE; BACTERIUM ISOLATE; CANDIDA; CANDIDA DUBLINIENSIS; CANDIDA FAMATA; CANDIDA GUILLIERMONDII; CANDIDA INCONSPICUA; CANDIDA KEFYR; CANDIDA KRUSEI; CANDIDA LUSITANIAE; CANDIDA NORVEGENSIS; CANDIDA PELLICULOSA; CANDIDA RUGOSA; CANDIDA ZEYLANOIDES; CONTROLLED STUDY; CULTURE MEDIUM; DRUG SCREENING; DRUG SENSITIVITY; ETEST METHOD; INCUBATION TIME; INTERMETHOD COMPARISON; LABORATORY TEST; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OBSERVER VARIATION; PRIORITY JOURNAL; YARROWIA LIPOLYTICA;

ANTIFUNGAL AGENTS; BLOOD; CANDIDA; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; TRIAZOLES;

BACTERIA (MICROORGANISMS); CANDIDA; CANDIDA DUBLINIENSIS; CANDIDA INCONSPICUA; CANDIDA RUGOSA; CANDIDA ZEYLANOIDES; CLAVISPORA LUSITANIAE; DEBARYOMYCES HANSENII; ISSATCHENKIA ORIENTALIS; KLUYVEROMYCES MARXIANUS; PICHIA ANOMALA; PICHIA GUILLIERMONDII; PICHIA NORVEGENSIS; YARROWIA LIPOLYTICA;

EID: 0037337105     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.41.3.1087-1090.2003     Document Type: Article

References (26)

1. Arendrup, M., B. Lundgren, I. M. Jensen, B. S. Hansen, and N. Frimodt-Møller. 2001. Comparison of Etest and a tablet diffusion test with the NC-CLS broth microdilution method for fluconazole and amphotericin B susceptibility testing Candida isolates. J. Antimicrob. Chemother. 47:521-526.
2. Barry, A. L., M. A. Pfaller, S. D. Brown, A. Espinel-Ingroff, M. A. Ghannoum, C. Knapp, R. P. Rennie, J. H. Rex, and M. G. Rinaldi. 2000. Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J. Clin. Microbiol. 38:3457-3459.
3. Barry, A. L., M. A. Pfaller, R. P. Rennie, P. C. Fuchs, and S. D. Brown. 2002. Precision and accuracy of fluconazole susceptibility tests by broth microdilution, Etest, and disk diffusion methods. Antimicrob. Agents Chemother. 46:1781-1784.
4. Dick, J. D., R. R. Rosengard, W. G. Merz, R. K. Stuart, G. M. Hutchins, and R. Saral. 1985. Fatal disseminated candidiasis due to amphotericin B-resistant Candida guilliermondii. Ann. Intern. Med. 102:67-68.
5. Dubé, M. P., P. N. R. Heseltine, M. G. Rinaldi, S. Evans, and B. Zawacki. 1994. Fungemia and colonization with nystatin-resistant Candida rugosa in a burn unit. Clin. Infect. Dis. 18:77-82.
6. Favel, A., A. Michel-Nguyen, C. Chastin, F. Trousson, A. Penaud, and P. Regli. 1997. In-vitro susceptibility pattern of Candida lusitaniae and evaluation of the Etest method. J. Antimicrob. Chemother. 39:591-596.
7. Hadfield, T. L., M. B. Smith, R. E. Winn, M. G. Rinaldi, and C. Guerra. 1987. Mycoses caused by Candida lusitaniae. Rev. Infect. Dis. 9:1006-1012.
8. Hazen, K. C. 1995. New and emerging yeast pathogens. Clin. Microbiol. Rev. 8:462-478.
9. Morace, G., G. Amato, F. Bistoni, G. Fadda, P. Marone, M. T. Montagna, S. Oliveri, L. Polonelli, R. Rigoli, I. Mancuso, S. LaFace, L. Masucci, L. Romano, C. Napoli, D. Tato, M. G. Buscema, C. M. C. Belli, M. M. Piccirillo, S. Conti, S. Covan, F. Fanti, C. Cavanna, F. D'Alo, and L. Pitzuna. 2002. Multicenter comparative evaluation of six commercial systems and the National Committee for Clinical Laboratory Standards M27-A broth microdilution method for fluconazole susceptibility testing of Candida species. J. Clin. Microbiol. 40:2953-2958.
10. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
11. Pfaller, M. A., S. A. Messer, Å. Karlsson, and A. Bolmström. 1998. Evaluation of the Etest method for determining fluconazole susceptibilities of 402 clinical yeast isolates by using three different agar media. J. Clin. Microbiol. 36:2586-2589.
12. Pfaller, M. A., S. A. Messer, and A. Bolmström. 1998. Evaluation of Etest for determining in vitro susceptibility of yeast isolates to amphotericin B. Diagn. Microbiol. Infect. Dis. 32:223-227.
13. Pfaller, M. A., S. A. Messer, R. J. Hollis, R. N. Jones, G. V. Doern, M. E. Brandt, and R. A. Hajjeh. 1999. Trends in species distribution and susceptibility to fluconazole among bloodstream isolates of Candida species in the United States. Diagn. Microbiol. Infect. Dis. 33:217-222.
14. Pfaller, M. A., S. A. Messer, A. Houston, K. Mills, A. Bolmström, and R. N. Jones. 2000. Evaluation of the Etest method for determining voriconazole susceptibilities of 312 clinical isolates of Candida species by using three different media. J. Clin. Microbiol. 38:3715-3717.
15. Pfaller, M. A., D. J. Diekema, R. N. Jones, H. S. Sader, A. C. Fluit, R. J. Hollis, S. A. Messer, and the SENTRY Participant Group. 2001. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program. J. Clin. Microbiol. 39:3254-3259.
16. Pfaller, M. A., S. A. Messer, K. Mills, A. Bolmström, and R. N. Jones. 2001. Evaluation of Etest method for determining posaconazole MICs for 314 clinical isolates of Candida species. J. Clin. Microbiol. 39:3952-3954.
17. Pfaller, M. A., S. A. Messer, K. Mills, A. Bolmström, and R. N. Jones. 2001. Evaluation of Etest method for determining caspofungin (MK-0991) susceptibilities of 726 clinical isolates of Candida species. J. Clin. Microbiol. 39: 4387-4389.
18. Pfaller, M. A., and D. J. Diekema. 2002. The role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibilities. J. Clin. Microbiol. 40:3551-3557.
19. Pfaller, M. A., S. A. Messer, R. J. Hollis, R. N. Jones, and D. J. Diekema. 2002. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemtic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob. Agents Chemother. 46:1723-1727.
20. Rex, J. H., M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghannoum, M. Lancaster, M. G. Rinaldi, T. J. Walsh, and A. L. Barry. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis. 24:235-247.
21. Rex, J. H., T. J. Walsh, J. D. Sobel, S. G. Filler, P. G. Pappas, W. E. Dismukes, and J. E. Edwards. 2000. Practice guidelines for the treatment of candidiasis. Clin. Infect. Dis. 30:662-678.
22. Simor, A. E., G. Goswell, L. Louie, M. Lee, and M. Louie. 1997. Antifungal susceptibility testing of yeast isolates from blood cultures by microbroth dilution and the Etest. Eur. J. Clin. Microbiol. Infect. Dis. 16:693-697.
23. Sullivan, D., and D. Coleman. 1997. Candida dubliniensis: an emerging opportunistic pathogen. Curr. Top. Med. Mycol. 8:15-25.
24. Warnock, D. W., E. M. Johnson, T. R. Rogers, et al. 1998. Multi-centre evaluation of the Etest method for antifungal drug susceptibility testing of Candida spp. and Cryptococcus neoformans. J. Antimicrob. Chemother. 42: 321-331.
25. Warren, N. G., and K. C. Hazen. 1999. Candida. Cryptococcus, and other yeasts of medical importance, p. 1184-1199. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 7th ed. ASM Press, Washington, D.C.
26. Wingard, J. R., W. G. Merz, M. G. Rinaldi, T. R. Johnson, J. E. Karp, and R. Saral. 1991. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N. Engl. J. Med. 325:1274-1277.